CYCN Valuation

Cyclerion Therapeutics Inc

Add to Watchlist

Advanced Chart

3.040

+0.66(27.731%)1D

Overview
Forecast
Valuation
Earnings

CYCN Relative Valuation

CYCN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CYCN is overvalued; if below, it's undervalued.

Historical Valuation

Cyclerion Therapeutics Inc (CYCN) is now in the Fair zone, suggesting that its current forward PS ratio of 3.74 is considered Fairly compared with the five-year average of -1.02. The fair price of Cyclerion Therapeutics Inc (CYCN) is between 0.68 to 2.82 according to relative valuation methord.

Relative Value

Fair Zone

0.68-2.82

Current Price：2.38

Fair

-0.07

Trailing

Forward

0.00

EV/EBITDA

Cyclerion Therapeutics Inc. (CYCN) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -0.27. The thresholds are as follows: Strongly Undervalued below -1.69, Undervalued between -1.69 and -0.98, Fairly Valued between 0.44 and -0.98, Overvalued between 0.44 and 1.14, and Strongly Overvalued above 1.14. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-0.03

EV/EBIT

Cyclerion Therapeutics Inc. (CYCN) has a current EV/EBIT of -0.03. The 5-year average EV/EBIT is -0.44. The thresholds are as follows: Strongly Undervalued below -2.15, Undervalued between -2.15 and -1.30, Fairly Valued between 0.41 and -1.30, Overvalued between 0.41 and 1.26, and Strongly Overvalued above 1.26. The current Forward EV/EBIT of -0.03 falls within the Historic Trend Line -Fairly Valued range.

3.74

Cyclerion Therapeutics Inc. (CYCN) has a current PS of 3.74. The 5-year average PS is 9.14. The thresholds are as follows: Strongly Undervalued below -18.31, Undervalued between -18.31 and -4.58, Fairly Valued between 22.87 and -4.58, Overvalued between 22.87 and 36.60, and Strongly Overvalued above 36.60. The current Forward PS of 3.74 falls within the Historic Trend Line -Fairly Valued range.

-0.06

P/OCF

Cyclerion Therapeutics Inc. (CYCN) has a current P/OCF of -0.06. The 5-year average P/OCF is -0.88. The thresholds are as follows: Strongly Undervalued below -3.22, Undervalued between -3.22 and -2.05, Fairly Valued between 0.29 and -2.05, Overvalued between 0.29 and 1.47, and Strongly Overvalued above 1.47. The current Forward P/OCF of -0.06 falls within the Historic Trend Line -Fairly Valued range.

-0.06

P/FCF

Cyclerion Therapeutics Inc. (CYCN) has a current P/FCF of -0.06. The 5-year average P/FCF is -0.88. The thresholds are as follows: Strongly Undervalued below -3.20, Undervalued between -3.20 and -2.04, Fairly Valued between 0.29 and -2.04, Overvalued between 0.29 and 1.45, and Strongly Overvalued above 1.45. The current Forward P/FCF of -0.06 falls within the Historic Trend Line -Fairly Valued range.

Cyclerion Therapeutics Inc (CYCN) has a current Price-to-Book (P/B) ratio of 0.85. Compared to its 3-year average P/B ratio of 1.29 , the current P/B ratio is approximately -33.93% higher. Relative to its 5-year average P/B ratio of 1.45, the current P/B ratio is about -41.24% higher. Cyclerion Therapeutics Inc (CYCN) has a Forward Free Cash Flow (FCF) yield of approximately -37.08%. Compared to its 3-year average FCF yield of -193.94%, the current FCF yield is approximately -80.88% lower. Relative to its 5-year average FCF yield of -143.25% , the current FCF yield is about -74.12% lower.

0.85

P/B

Median3y

1.29

Median5y

1.45

-37.08

FCF Yield

Median3y

-193.94

Median5y

-143.25

Competitors Valuation Multiple

The average P/S ratio for CYCN's competitors is 4.73, providing a benchmark for relative valuation. Cyclerion Therapeutics Inc Corp (CYCN) exhibits a P/S ratio of 3.74, which is -20.86% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

CYCN.O

Cyclerion Therapeutics Inc

Artelo Biosciences Inc

Loss

8.15M

GLMD.O

Galmed Pharmaceuticals Ltd

Loss

8.05M

PTIX.O

Protagenic Therapeutics Inc

Vyne Therapeutics Inc

19.37

-65.15%

8.00M

Performance Decomposition

Market capitalization of CYCN increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of CYCN in the past 1 year is driven by Unknown.